Acesso livre
Acesso livre

Interesse Geral

[Comunicado de imprensa – ainda não publicado] J&J afirma que dose de reforço depois de 2 meses propiciou 75% de proteção contra COVID-19 moderada a grave globalmente, sendo 94% desses casos nos EUA.

27 Set, 2021 | 11:39h

Comunicado de imprensa: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Comentários:

Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT

J&J booster 94% effective against severe COVID, company says – CIDRAP

Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN

 

Comentários no Twitter

(fio – clique para saber mais)

(fio – clique para saber mais)

 

Perspectiva | Desculpe, mas uma infecção por coronavírus pode não ser o suficiente para proteger você – “Qualquer um que prefira ter COVID-19 do que se vacinar está fazendo uma aposta dupla: que a imunidade se mantenha, e os sintomas, não.”

27 Set, 2021 | 11:35h

Sorry, a Coronavirus Infection Might Not Be Enough to Protect You – The Atlantic

[Comunicado de imprensa – ainda não publicado] Pfizer anuncia que sua vacina contra COVID-19 produz forte resposta imune em crianças de 5 a 11 anos.

27 Set, 2021 | 11:00h

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years – Pfizer and BioNTech

Comentários:

Covid-19 vaccine for 5- to 11-year-olds is safe and shows ‘robust’ antibody response, Pfizer says – CNN

Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP

Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says – STAT

Expert reaction to press release giving topline results from Pfizer and BioNTech from their phase 2/3 trial looking at safety and antibody responses from their COVID-19 vaccine in children aged 5 to 11 – Science Media Centre

 

Comentários no Twitter

(fio – clique para saber mais)

(fio – clique para saber mais)

 

Desatrelando a vacinação da política: um chamado para a ação.

27 Set, 2021 | 10:57h

Uncoupling vaccination from politics: a call to action – The Lancet

Seis regras que definirão nosso segundo inverno pandêmico.

27 Set, 2021 | 10:52h

Six Rules That Will Define Our Second Pandemic Winter – The Atlantic

Editorial | Questões de autoria e publicação: créditos e credibilidade.

27 Set, 2021 | 10:38h

Authorship and Publication Matters: Credit and Credibility – Anesthesiology

Conteúdo relacionado: When is ‘self-plagiarism’ OK? New guidelines offer researchers rules for recycling text – Science

 

Comentário no Twitter

 

OMS/Europa afirma que 5.000 mortes por câncer relacionado ao consumo de álcool poderiam ser evitadas todo ano por meio da duplicação das taxas sobre o álcool na região da Europa.

27 Set, 2021 | 10:36h

5000 alcohol-related cancer deaths could be prevented every year by doubling alcohol taxes in the European Region, says WHO/Europe – World Health Organization

Estudo original: Modelling the impact of increased alcohol taxation on alcohol-attributable cancers in the WHO European Region – The Lancet Regional Health – Europe

Conteúdos relacionados:

Fiscal policies for diet and the prevention of noncommunicable diseases – World Health Organization

The Lancet taskforce on NCDs and economics

To improve global health, tax the things that are killing us – Financial Times

Reducing cardiovascular disease burden through targeted dietary policies

Fiscal policies for the prevention of diseases

Relatório do CDC | Vacina da Moderna está associada a alta efetividade (93%) contra hospitalização por Covid-19 em comparação às vacinas da Pfizer (88%) e da J&J (71%).

20 Set, 2021 | 13:59h

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 – CDC Morbidity and Mortality Weekly Report

Comentários:

Moderna’s vaccine is the most effective, but Pfizer and J&J also protect well, CDC-led study says – CNN

CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI

 

Comentário no Twitter

 

Revisão | Sintomas de “long COVID” em crianças raramente persistem por mais de 3 meses.

20 Set, 2021 | 13:57h

Comunicado de imprensa: Long COVID symptoms in children rarely persist beyond three months –  Murdoch Children’s Research Institute

Estudo original: How Common Is Long COVID in Children and Adolescents? – The Pediatric Infectious Disease Journal

Comentário: Long Covid in children and adolescents is less common than previously feared – The Guardian

Conteúdos relacionados:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

 

Comentário no Twitter (fio – clique para saber mais)

 

Um painel da FDA afirma que somente americanos de alto risco e os maiores de 65 anos deveriam tomar as doses de reforço contra Covid.

20 Set, 2021 | 13:56h

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

Ver também:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Conteúdos relacionados:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.